WallStSmart

Monte Rosa Therapeutics Inc (GLUE)vsVertex Pharmaceuticals Inc (VRTX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 18317% more annual revenue ($12.95B vs $70.33M). VRTX leads profitability with a 30.7% profit margin vs -186.2%. VRTX earns a higher WallStSmart Score of 58/100 (C).

GLUE

Hold

36

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 6/9Altman Z: 0.02

VRTX

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 9.0Value: 6.0Quality: 8.0
Piotroski: 4/9Altman Z: 3.69
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GLUE.

VRTXUndervalued (+46.6%)

Margin of Safety

+46.6%

Fair Value

$974.60

Current Price

$515.02

$459.58 discount

UndervaluedFair: $974.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GLUE3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
325.8%10/10

Revenue surging 325.8% year-over-year

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

VRTX4 strengths · Avg: 9.8/10
Profit MarginProfitability
30.7%10/10

Keeps 31 of every $100 in revenue as profit

Operating MarginProfitability
37.8%10/10

Strong operational efficiency at 37.8%

Altman Z-ScoreHealth
3.6910/10

Safe zone — low bankruptcy risk

Market CapQuality
$137.57B9/10

Large-cap with strong market position

Areas to Watch

GLUE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$880.99M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-26.4%2/10

ROE of -26.4% — below average capital efficiency

Free Cash FlowQuality
$-42.54M2/10

Negative free cash flow — burning cash

VRTX3 concerns · Avg: 3.3/10
PEG RatioValuation
2.384/10

Expensive relative to growth rate

P/E RatioValuation
34.9x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-39.0%2/10

Earnings declined 39.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : GLUE

The strongest argument for GLUE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 325.8% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.7% and operating margin at 37.8%. Revenue growth of 11.8% demonstrates continued momentum.

Bear Case : GLUE

The primary concerns for GLUE are EPS Growth, Market Cap, Return on Equity.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, EPS Growth.

Key Dynamics to Monitor

GLUE profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.

GLUE carries more volatility with a beta of 1.38 — expect wider price swings.

GLUE is growing revenue faster at 325.8% — sustainability is the question.

VRTX generates stronger free cash flow (546M), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (58/100 vs 36/100), backed by strong 30.7% margins and 11.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Monte Rosa Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?